Search global stocks & ETFs...Ctrl K
Learn Mode
Viking Therapeutics IncVKTX
$37.48
-$1.53 (-3.922%)
$37.37
-$0.11 (-0.296%)
VKTX
Stock Profile
07-29
Recommended Metric
Score Card
Explore Scores Tab
2.73
Average
Valuation Score
Key Score
5.00
Very Good
Management
1.00
Very Bad
Growth
--
--
Profitability
5.00
Very Good
Fin. Health
1.00
Very Bad
Dividends
--
--
Analyst
3.00
Average
Insider Transactions
Explore Insider Tab ›Buy Transactions
Sell Transactions
Peers
Select stocks to compare
Price Targets & Ratings
View Analysis
1-year price targets, ending May 11, 2027
Current
$37.48
Baseline
High
$131.25
▲
250.19%
Avg
$96.01
▲
156.16%
Low
$34.34
▼
-8.38%
Analyst Ratings based on 26 Analysts
Strong Buy
935%
Buy
1454%
Hold
312%
Sell
000%
Strong Sell
000%
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company is headquartered in San Diego, California and currently employs 59 full-time employees. The company went IPO on 2015-04-29. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. The company is evaluating an oral formulation of VK2735 in a Phase II trial. The company is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.Read More